Orphan Drug Status For LPA1 Antagonist AM152 For Treatment Of Idiopathic Pulmonary Fibrosis

Amira Pharmaceuticals, Inc. announced today that AM152, the company's lead LPA1 antagonist, has been granted an orphan drug designation by the U.S. Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis. Commonly referred to as IPF,   idiopathic pulmonary fibrosisis scarring or thickening of the lungs without a known cause.   This fibrotic disease affects the lungs of patients and their ability to breathe.  No one knows what causes pulmonary fibrosis or why some people get it but the condition is believed to result from an inflammatory response to an unknown substance. "Idiopathic" means no cause can be found.      read more

Read the whole article on

More from